AU759557B2 - Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood - Google Patents
Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood Download PDFInfo
- Publication number
- AU759557B2 AU759557B2 AU14184/99A AU1418499A AU759557B2 AU 759557 B2 AU759557 B2 AU 759557B2 AU 14184/99 A AU14184/99 A AU 14184/99A AU 1418499 A AU1418499 A AU 1418499A AU 759557 B2 AU759557 B2 AU 759557B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- perfluorocarbon
- accordance
- liquid
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000007788 liquid Substances 0.000 title claims description 84
- 238000009423 ventilation Methods 0.000 title description 32
- 239000002473 artificial blood Substances 0.000 title description 17
- 150000002430 hydrocarbons Chemical class 0.000 title description 8
- 229930195733 hydrocarbon Natural products 0.000 title description 7
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 37
- 210000004072 lung Anatomy 0.000 claims description 36
- 239000007789 gas Substances 0.000 claims description 34
- 241000124008 Mammalia Species 0.000 claims description 17
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 25
- 239000000203 mixture Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 238000009835 boiling Methods 0.000 description 15
- 210000003437 trachea Anatomy 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- -1 perfluorocarbon compound Chemical class 0.000 description 11
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical class C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 230000002685 pulmonary effect Effects 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229920000260 silastic Polymers 0.000 description 6
- 239000012808 vapor phase Substances 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 4
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethylcyclohexane Chemical compound CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 4
- 235000019000 fluorine Nutrition 0.000 description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 4
- SEKSWDGNGZWLDU-UHFFFAOYSA-N 1,1,2,2-tetramethylcyclohexane Chemical compound CC1(C)CCCCC1(C)C SEKSWDGNGZWLDU-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 241001504519 Papio ursinus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000005264 electron capture Effects 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- SYLFCPLQRJNYJN-UHFFFAOYSA-N 1,1,2,2,3,4,5,6-octafluoro-3,4,5,6-tetrakis(trifluoromethyl)cyclohexane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(C(F)(F)F)C(F)(C(F)(F)F)C1(F)C(F)(F)F SYLFCPLQRJNYJN-UHFFFAOYSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- KRFHQQXJAGLZLP-UHFFFAOYSA-N 1-ethyl-2,4-dimethylcyclohexane Chemical compound CCC1CCC(C)CC1C KRFHQQXJAGLZLP-UHFFFAOYSA-N 0.000 description 2
- NHCREQREVZBOCH-UHFFFAOYSA-N 1-methyl-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene Chemical compound C1CCCC2C(C)CCCC21 NHCREQREVZBOCH-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GWESVXSMPKAFAS-UHFFFAOYSA-N Isopropylcyclohexane Chemical compound CC(C)C1CCCCC1 GWESVXSMPKAFAS-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 150000001934 cyclohexanes Chemical class 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001211 electron capture detection Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- UWEYRJFJVCLAGH-UHFFFAOYSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F UWEYRJFJVCLAGH-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- QZUJWESVOYGMQY-UHFFFAOYSA-N 2-ethyl-1,3-dimethylcyclohexane Chemical compound CCC1C(C)CCCC1C QZUJWESVOYGMQY-UHFFFAOYSA-N 0.000 description 1
- YSLKXMCOTLLYSD-UHFFFAOYSA-N 2-ethyl-1,4-dimethylcyclohexane Chemical compound CCC1CC(C)CCC1C YSLKXMCOTLLYSD-UHFFFAOYSA-N 0.000 description 1
- ZQIGRFMPOSZOOL-UHFFFAOYSA-N 4-ethyl-1,2-dimethylcyclohexane Chemical compound CCC1CCC(C)C(C)C1 ZQIGRFMPOSZOOL-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229910021583 Cobalt(III) fluoride Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010059487 Lung hyperinflation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- WZJQNLGQTOCWDS-UHFFFAOYSA-K cobalt(iii) fluoride Chemical compound F[Co](F)F WZJQNLGQTOCWDS-UHFFFAOYSA-K 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical class [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/975743 | 1997-11-20 | ||
| US08/975,743 US6167887B1 (en) | 1997-11-21 | 1997-11-21 | Selected C-10 perfluorinated hydrocarbons for liquid ventilation and artificial blood |
| PCT/US1998/024632 WO1999026604A2 (en) | 1997-11-20 | 1998-11-18 | Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1418499A AU1418499A (en) | 1999-06-15 |
| AU759557B2 true AU759557B2 (en) | 2003-04-17 |
Family
ID=25523336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU14184/99A Expired AU759557B2 (en) | 1997-11-20 | 1998-11-18 | Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6167887B1 (https=) |
| EP (1) | EP1037619A4 (https=) |
| JP (1) | JP2003522094A (https=) |
| AU (1) | AU759557B2 (https=) |
| CA (1) | CA2311122C (https=) |
| WO (1) | WO1999026604A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2007081008A1 (ja) * | 2006-01-16 | 2009-06-11 | 旭硝子株式会社 | 新規なフッ素系界面活性剤および新規な含フッ素化合物 |
| AU2007249200B2 (en) * | 2006-05-15 | 2013-12-19 | Virginia Commonwealth University | Methods and compositions for controlled and sustained production and delivery of peroxides |
| JP5781727B2 (ja) | 2007-02-23 | 2015-09-24 | 株式会社ネクスト２１ | 血管攣縮の治療剤又は予防剤 |
| EP2252333A4 (en) * | 2008-02-13 | 2013-07-10 | Oxygen Biotherapeutics Inc | WOUND AND TISSUE THERAPY ON GAS BASIS |
| US8404752B2 (en) * | 2008-07-18 | 2013-03-26 | Oxygen Biotherapeutics, Inc. | Method of treating traumatic brain injury |
| US8343515B2 (en) | 2008-11-25 | 2013-01-01 | Oxygen Biotherapeutics, Inc. | Perfluorocarbon gel formulations |
| MX2011005536A (es) * | 2008-11-25 | 2011-08-17 | Oxygen Biotherapeutics Inc | Formulas de gel de perfluorocarbono. |
| US20100144597A1 (en) * | 2008-12-10 | 2010-06-10 | Ward Kevin R | Novel combinatorial approaches to enhancing oxygen transport to tissues |
| WO2011014247A1 (en) * | 2009-07-28 | 2011-02-03 | Oxygen Biotherapeutics, Inc. | Method to increase oxygen in male and female sexual organs through the topical use of perfluorocarbons |
| EP2459235B1 (en) * | 2009-07-31 | 2014-04-23 | Koninklijke Philips N.V. | Perfluoro-t-butyl cyclohexane for use in imaging |
| WO2011116277A1 (en) * | 2010-03-19 | 2011-09-22 | Oxygen Biotherapeutics, Inc. | Perfluorocarbon eye cream formulations |
| WO2012044963A2 (en) | 2010-10-01 | 2012-04-05 | Oxygen Biotherapeutics, Inc. | Perfluorocarbons for use in treating pruritus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3911138B1 (en) | 1973-02-26 | 1996-10-29 | Childrens Hosp Medical Center | Artificial blood and method for supporting oxygen transport in animals |
| US4453028A (en) | 1982-03-29 | 1984-06-05 | Lagow Richard J | Perfluorinated compounds with cyclohexyl groups |
| USRE33451E (en) | 1982-04-12 | 1990-11-20 | Children's Hospital Medical Center | Artificial blood and other gas transport agents |
| US4443480A (en) * | 1982-04-12 | 1984-04-17 | Children's Hospital Medical Center | Artificial blood and other gas transport agents |
| US4686024A (en) | 1985-02-01 | 1987-08-11 | The Green Cross Corporation | Novel perfluoro chemicals and polyfluorinated compounds and process for production of the same |
| US5437272A (en) | 1991-05-01 | 1995-08-01 | Alliance Pharmaceutical Corp. | Perfluorocarbon associated gas exchange |
| ES2124260T3 (es) | 1991-05-03 | 1999-02-01 | Alliance Pharma | Respiracion liquida parcial de fluorocarbonos. |
| US5146014A (en) | 1991-07-02 | 1992-09-08 | Air Products And Chemicals, Inc. | Perfluoroethyldimethyl cyclohexane |
| US5674913A (en) | 1994-05-13 | 1997-10-07 | Synthetic Blood International, Inc. | Method for assisting normal breathing in a mammal having a lung disorder |
| US5840767A (en) | 1995-12-01 | 1998-11-24 | Synthetic Blood International, Inc. | Perfluorocarbons for biological gas exchange and method |
| JP4289499B2 (ja) * | 2004-09-06 | 2009-07-01 | 城南鋼鉄工業株式会社 | 扉のロック機構 |
-
1997
- 1997-11-21 US US08/975,743 patent/US6167887B1/en not_active Expired - Lifetime
-
1998
- 1998-11-18 CA CA002311122A patent/CA2311122C/en not_active Expired - Fee Related
- 1998-11-18 WO PCT/US1998/024632 patent/WO1999026604A2/en not_active Ceased
- 1998-11-18 JP JP2000521806A patent/JP2003522094A/ja active Pending
- 1998-11-18 AU AU14184/99A patent/AU759557B2/en not_active Expired
- 1998-11-18 EP EP19980958073 patent/EP1037619A4/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| MOORE ET AL OXYGEN CARRYING COLLOIDAL BLOOD SUBSTITUTES 5TH INT.SYMP ON PERFLUOROCARBON BLOOD SUBSTITUTES, MAINZ, MARCH 1981, PGS.51-60 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999026604A3 (en) | 1999-10-14 |
| EP1037619A4 (en) | 2001-08-13 |
| CA2311122C (en) | 2004-04-13 |
| WO1999026604A2 (en) | 1999-06-03 |
| EP1037619A2 (en) | 2000-09-27 |
| AU1418499A (en) | 1999-06-15 |
| CA2311122A1 (en) | 1999-06-03 |
| JP2003522094A (ja) | 2003-07-22 |
| US6167887B1 (en) | 2001-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU759557B2 (en) | Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood | |
| CA1042799A (en) | Perfluorocyclocarbons as gas transport agents in animals | |
| Jones | Desflurane and sevoflurane: inhalation anaesthetics for this decade? | |
| JP6585139B2 (ja) | 麻酔を誘発する方法 | |
| US4762856A (en) | Anesthetic composition and method of using the same | |
| EP0091820A1 (en) | Artificial blood and other gas transport agents | |
| Clark Jr et al. | Ring versus straight chain perfluorocarbon emulsions for perfusion media | |
| Modell et al. | Liquid ventilation of primates | |
| EP0758886B1 (en) | Use of perfluorocarbons for assisting normal breathing in mammals having lung disorders | |
| Hudson et al. | Pharmacokinetics of inhaled anesthetics | |
| Pihlainen et al. | Analytical toxicology of fluorinated inhalation anaesthetics | |
| Koblin et al. | Polyhalogenated methyl ethyl ethers: solubilities and anesthetic properties | |
| Tsatsakis et al. | Fatal and non-fatal outcome by accidental intoxication with paint thinner | |
| Levine et al. | A fatality from sevoflurane abuse | |
| Thomas et al. | Effect of hemodialysis on plasma cholinesterase | |
| FABIAN et al. | Laboratory and clinical investigation of some newly synthesized fluorocarbon anesthetics | |
| Loeckinger et al. | Pulmonary gas exchange in coronary artery surgery patients during sevoflurane and isoflurane anesthesia | |
| Rae | Theory versus practice in the Twentieth-Century search for the ideal anaesthetic gas | |
| Monticelli et al. | Another case of diethyl ether intoxication? A case report focusing on toxicological analysis | |
| Aljerf et al. | Halothane Anesthesia–Fact or Fallacy | |
| Kalman et al. | Minimum alveolar concentration of halothanediethyl‐ether azeotrope | |
| Yang et al. | Effects of grade B liver dysfunction on the level of free hexafluoroisopropanol of sevoflurane metabolites in patients with abdominal surgery | |
| Zelkowitz et al. | Effects of ether and halothane inhalation on pulmonary surfactant | |
| Mazze et al. | Metabolism of synthane: comparison with in vivo and in vitro defluorination of other halogenated hydrocarbon anaesthetics | |
| Aim | Exploratory and Newer Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |